Regenxbio
RGNX
7.56
-0.04
-0.53%
Regenxbio
US · RGNX
#3748 by market cap
Listed 2015
7.56
-0.04
-0.53%
Live - 5344 symbols - heartbeat 423s ago
· 2026-10-08 10:00
Pre-market
7.48
-1.51%
After-hours
7.61
+0.21%
Overnight
7.86
+3.49%
- Market cap
- 498.73M
- P/E (TTM)i
- -2.00
- P/Bi
- 6.95
- EPSi
- -3.76
- Div yieldi
- 0.00%
- 52W posi
- 20%
Reader sentiment
Are you bullish or bearish on RGNX?
Anonymous reader poll. Unscientific, not investment advice.
✦ Quant Ownership Signal how this is computed
Distributing
- The number of reporting institutions increased by 2 in the most recent period (2026/Q3).
- Total institutional ownership fell 13.5 percentage points.
Institutional ownership
- Held by institutions
- 66.07% -13.45pp
- Institutions
- 206 +2
- As of
- 2026/Q3 vs. prior period
Ownership vs. money flow
AlignedInstitutions trimmed shares last reporting period, and the stock has seen net outflows in main-fund flow over the last 20 trading sessions - the two line up.
Institutional ownership changes are reported quarterly with a lag; fund-flow data is daily. Treat this as a directional cross-check, not a precise timing signal.
Holder types
Mutual Fund37.71%
Hedge Fund18.35%
Individual/Insider6.69%
Public Company5.93%
Insurance Company1.46%
Private Company1.43%
VC/PE Fund1.12%
Other27.24%
Top holders as of 2026-06-30
BlackRock
9.69% · 6.40M sh
Redmile Group, LLC
6.62% · 4.37M sh
Allan Fox
4.82% · 3.18M sh
State Street Global Advisors
4.50% · 2.97M sh
Vanguard Capital Management, LLC
3.70% · 2.44M sh
J.P. Morgan Asset Management, Inc.
3.24% · 2.14M sh
Morgan Stanley
2.90% · 1.92M sh
Vanguard Portfolio Management, LLC
2.05% · 1.36M sh
AQR Capital Management
2.05% · 1.35M sh
Marshall Wace LLP
1.95% · 1.28M sh
Bar length is relative to the largest holder shown here, not to 100% of the company.
Insiders
50 filings tracked · 33 buys · 17 sells
| Name | Role | Stake |
|---|---|---|
| Allan Fox | Chairperson | 4.82% |
| Kenneth Mills | Chief Executive Officer | 0.67% |
| Vittal Vasista | Chief Financial Officer | 0.29% |
| Gregory Ciongoli | Independent Director | 0.16% |
| Patrick Christmas | Chief Legal Officer | 0.15% |
| Craig Malzahn | Executive Vice President, Product Development & CTO | 0.12% |
| Olivier Danos | Chief Scientific Officer | 0.09% |
| Curran Simpson | Chief Operating Officer | 0.08% |
| Stephen Pakola | Chief Medical Officer | 0.08% |
| Jennifer Zachary | Independent Director | 0.03% |
Insider transactions most recent Form 4 filings
| Date | Name | Role | Type | Shares | Price |
|---|---|---|---|---|---|
| 2026-08-31 | Mitchell Chan | Chief Financial Officer | Sale to Issuer | -4,902 | $9.32 |
| 2026-08-31 | Craig Malzahn | Executive Vice President, Product Development & CTO | Sale to Issuer | -234 | $9.32 |
| 2026-08-26 | Gregory Ciongoli | Independent Director | Open Market Acquisition | +102,603 | $9.14–9.36 |
| 2026-08-24 | Gregory Ciongoli | Independent Director | Other Acquisition | +15,432 | -- |
| 2026-08-24 | Gregory Ciongoli | Independent Director | Other Derivative Acquisition | +69,609 | $8.91 |
| 2026-07-31 | Stephen Pakola | Chief Medical Officer | Sale to Issuer | -7,468 | $9.69 |
| 2026-07-31 | Patrick Christmas | Chief Legal Officer | Sale to Issuer | -4,699 | $9.69 |
| 2026-07-01 | Stephen Pakola | Chief Medical Officer | Derivative Exercise and Sale | -2,161 | $7.86–13.64 |
| 2026-06-30 | Curran Simpson | Chief Operating Officer | Sale to Issuer | -6,818 | $13.09 |
| 2026-06-30 | Stephen Pakola | Chief Medical Officer | Derivative Exercise and Sale | -36,725 | $7.86–12.86 |
| 2026-06-29 | Curran Simpson | Chief Operating Officer | Other Acquisition | +2,404 | $7.00–10.18 |
| 2026-06-28 | Stephen Pakola | Chief Medical Officer | Automatic Disposition | -19,608 | $11.04 |
| 2026-05-28 | David Stump | Independent Director | Other Acquisition | +9,807 | -- |
| 2026-05-28 | David Stump | Independent Director | Other Derivative Acquisition | +46,600 | $7.01 |
| 2026-05-28 | George Migausky | Independent Director | Other Acquisition | +9,807 | -- |
| 2026-05-28 | George Migausky | Independent Director | Other Derivative Acquisition | +46,600 | $7.01 |
| 2026-05-28 | Argeris Karabelas | Lead Independent Director | Other Acquisition | +9,807 | -- |
| 2026-05-28 | Argeris Karabelas | Lead Independent Director | Other Derivative Acquisition | +46,600 | $7.01 |
| 2026-05-28 | Allan Fox | Chairperson | Other Acquisition | +9,807 | -- |
| 2026-05-28 | Allan Fox | Chairperson | Other Derivative Acquisition | +46,600 | $7.01 |
Form 4 filings, most recent per company. "Other Derivative Acquisition" rows are mostly RSU/option vesting, not open-market buying - the Type column says which.
Quote time 2026-10-08 10:00:13 · For reference only, not investment advice and not tailored to your situation.